UNITED STATES

 SECURITIES AND EXCHANGE COMMISSION

 Washington, D.C. 20549

 

FORM 12b-25 

NOTIFICATION OF LATE FILING

OMB APPROVAL

OMB Number: 3235-0058

Expires: February 28, 2022

Estimated average burden hours

per response ............ 2.50

SEC File Number: 000-54933

CUSIP Number: 45252A 107

 

 (Check one) [X] Form 10-K [  ] Form 20-F [  ] Form 11-K [  ] Form 10-Q [  ] Form 10-D [  ] Form N-SAR
  [  ] Form N-CSR

 

For period ended 12/31/2020

 

[  ] Transition Report on Form 10-K

 

[  ] Transition Report on Form 20-F

 

[  ] Transition Report on Form 11-K

 

[  ] Transition Report on Form 10-Q

 

[  ] Transition Report on Form N-SAR

 

For the Transition Period Ended: ___________________________

 

Read Instruction (on back page) Before Preparing Form. Please Print or Type

Nothing in this form shall be construed to imply that the Commission has verified any information contained herein.

 

If the notification relates to a portion of the filing checked above, identify the item(s) to which the notification relates:

 

 

 

PART I — REGISTRANT INFORMATION

 

Immune Therapeutics, Inc.

Full Name of Registrant

 

TNI BioTech, Inc.

Former Name if Applicable

 

2431 Aloma Ave, Suite 124

Address of Principal Executive Office (Street and Number)

 

Winter Park, FL 32792

City, State and Zip Code

 

 

 

 
 

 

PART II — RULE 12b-25(b) AND (c)

 

If the subject report could not be filed without unreasonable effort or expense and the registrant seeks relief pursuant to Rule 12b-25(b), the following should be completed. (Check box if appropriate.)

 

  (a) The reasons described in reasonable detail in Part III of this form could not be eliminated without unreasonable effort or expense;
[X] (b) The subject annual report, semi-annual report, transition report on Form 10-K, Form 20-F, Form 11-K, Form N-SAR or Form N-CSR, or portion thereof, will be filed on or before the 15th calendar day following the prescribed due date; or the subject quarterly report or transition report on Form 10-Q, or subject distribution report on Form 10-D, or portion thereof, will be filed on of before the fifth calendar day following the prescribed due date; and
  (c) The accountant’s statement or other exhibit required by Rule 12b-25(c) has been attached if applicable.

 

PART III — NARRATIVE

 

State below in reasonable detail the reasons why Forms 10-K, 20-F, 11-K, 10-Q, N-SAR, N-CSR, or the transition report or portion thereof, could not be filed within the prescribed time period. (Attach extra sheets if needed)

 

The Registrant is unable to file the Form 10-K for the period ending December 31, 2020 within the prescribed time period due to a delay in obtaining and compiling information required to be included in the Registrant ‘s Form 10-K, which delay could not be eliminated by the Registrant without unreasonable effort and expense. In accordance with Rule 12b-25 of the Securities Exchange Act of 1934, as amended, the Registrant will file its Form 10-K no later than the fifteenth calendar day following the prescribed due date.

 

PART IV — OTHER INFORMATION

 

(1) Name and telephone number of person to contact in regard to this notification

 

Kevin J. Phelps   888   613-8802
(Name)   (Area Code)   (Telephone Number)
         

(2) Have all other periodic reports required under Section 13 or 15(d) of the Securities Exchange Act of 1934 or Section 30 of the Investment Company Act of 1940 during the preceding 12 months or for such shorter period that the registrant was required to file such report(s) been filed? If the answer is no, identify report(s). [X] Yes [_] No

 

(3) Is it anticipated that any significant change in results of operations from the corresponding period for the last fiscal year will be reflected by the earnings statements to be included in the subject report or portion thereof? [_] Yes [X] No

 

If so, attach an explanation of the anticipated change, both narratively and quantitatively, and, if appropriate, state the reasons why a reasonable estimate of the results cannot be made.

 

2
 

 

Immune Therapeutics, Inc.

(Name of Registrant as Specified in Charter)

 

has caused this notification to be signed on its behalf by the undersigned thereunto duly authorized.

 

Date: March 31, 2021 By: /s/ Kevin J. Phelps
  Name: Kevin J. Phelps
  Title: Chief Executive Officer

 

INSTRUCTION: The form may be signed by an executive officer of the registrant or by any other duly authorized representative. The name and title of the person signing the form shall be typed or printed beneath the signature. If the statement is signed on behalf of the registrant by an authorized representative (other than an executive officer), evidence of the representative’s authority to sign on behalf of the registrant shall be filed with the form.

 

ATTENTION 

Intentional misstatements or omissions of fact constitute Federal Criminal Violations (See 18 U.S.C. 1001).

 

3

Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Dec 2021 to Jan 2022 Click Here for more Immune Therapeutics (PK) Charts.
Immune Therapeutics (PK) (USOTC:IMUN)
Historical Stock Chart
From Jan 2021 to Jan 2022 Click Here for more Immune Therapeutics (PK) Charts.